CoChat

Adiponectin, type 2 diabetes and cardiovascular risk

Lindberg, Søren, Jensen, Jan Skov, Bjerre, Mette, Pedersen, Sune H, Frystyk, Jan, Flyvbjerg, Allan, Galatius, Søren, Jeppesen, Jørgen, Mogelvang, Rasmus · 2015 · European Journal of Preventive Cardiology

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background Adiponectin is viewed as an insulin-sensitizing hormone with anti-inflammatory effects. In accordance, plasma adiponectin is decreased in metabolic disorders including type 2 diabetes mellitus (T2DM). However, in spite of the apparently beneficially effects, recent data from large prospective studies have consistently linked high adiponectin levels with increased cardiovascular (CV) disease and mortality, thus questioning the positive view on adiponectin. Accordingly, we investigated the relationship between adiponectin, incident T2DM and subsequently CV events. Methods We prospectively followed 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years (IQR 8.0-9.1 years). During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death). Results Participants with increasing adiponectin had reduced risk of developing T2DM (p Conclusions In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.

Overview

Integrity signals

Registry

Crossref · 10.1177/2047487313514894

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 66

Metadata

Authors
Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., & Mogelvang, R.
Affiliations
  • Bispebjerg Hospital (DK)
  • University of Copenhagen (DK)
  • Aarhus University (DK)
  • Gentofte Hospital (DK)
  • Bispebjerg University Hospital, Copenhagen, Denmark
Corresponding author
Lindberg, Søren
Venue
European Journal of Preventive Cardiology
Published
2013-11-21
Volume
22
Issue
3
Pages
276-283
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2138493608
Cited by
66
References
29
Citations by year
2025: 4 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 19 · 2019: 2 · 2018: 7 · 2017: 2 · 2016: 7 · 2015: 6 · 2014: 5
FWCI
4.36
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Hjerteforeningen (12-04-R90-A3871-22735)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
adiponectin, type 2 diabetes, cardiovascular risk, cardiovascular events, myocardial infarction, ischemic stroke, cardiovascular mortality, insulin sensitivity, anti-inflammatory activity, incident diabetes risk, plasma adiponectin levels
MeSH terms
Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Denmark, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Up-Regulation, Chi-Square Distribution, Linear Models, Proportional Hazards Models, Risk Assessment, Adiponectin, Young Adult, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adiponectin, type 2 diabetes and cardiovascular risk. https://app.cochat.ai/papers/10.1177/2047487313514894
The paper
Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., & Mogelvang, R. (2015). Adiponectin, type 2 diabetes and cardiovascular risk. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487313514894

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.